Rethinking Clinical Trials

OCTOBER 26, 2023

point of care diagnostic tests, provide broad access to curative Hepatitis C medications with a national subscription model, with Medicare co-pay assistance and commercial insurance coverage. The initiative would bring to the U.S.

Clinical Research 141

Clinical Research Clinical Trials Clinical Trials Research 141

XTalks

NOVEMBER 3, 2022

Demand for Lilly’s GIP/GLP-1 receptor agonist Mounjaro is also rising because of high patient demand since the drug’s May 13 FDA approval and expanding insurance coverage. The company is currently conducting a study to demonstrate Mounjaro’s weight loss effects and secured an FDA Fast Track tag in the obesity indication.

Sales 98

Sales FDA Approval Production Insulin 98

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. We have products that are living therapies. How do you characterise and think about the potency of a living drug when that final product is still changing and dividing? One challenge is in potency.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

Drug Discovery World

MAY 22, 2023

But are these price tags a barrier to access? From private plans to government programmes, there are workable systems that support CGTs, proven by MediCare’s support of CAR-T and the UK’s National Health Service coverage. CGTs are classified as ‘living drugs’ and are much more complex entities than other biologics.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

XTalks

FEBRUARY 27, 2024

Addressing the high price tag, Iovance’s commercial chief Jim Ziegler said, “Payers have expressed their appreciation for the value proposition for Amtagvi.” He explained that based on communications with payers so far, the company expects coverage to be similar to that of existing CAR-T therapies, with a prior authorization requirement.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

XTalks

JUNE 9, 2021

Aducanumab Controversy and Price Tag. Industry experts say that while 85 percent to 90 percent of patients in the US are eligible to be covered for the drug by Medicare, it is likely that other insurers, and even Medicare, will limit their coverage to the type of patients who participated in the trial. Clinical Evidence.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

XTalks

AUGUST 23, 2021

Payer coverage decisions could have a greater impact on this if large health insurers decide to add aducanumab to their formulary. With a $56,000 price tag for a year’s worth of treatment, Aduhelm is far from the most expensive drug on the market. This is another case in which careful clinical trial design is of the utmost importance.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52